JDRF at the Partnering for Cures Conference
15
1 Juvenile Diabetes Research Juvenile Diabetes Research Foundation Foundation (JDRF) (JDRF) www.jdrf.o rg
-
Upload
train-central-station -
Category
Health & Medicine
-
view
1.395 -
download
0
description
The Juvenile Diabetes Research Foundation presents its R&D strategies at the 2009 Partnering for Cures conference in New York
Transcript of JDRF at the Partnering for Cures Conference
1
Juvenile Diabetes Research FoundationJuvenile Diabetes Research Foundation(JDRF) (JDRF)
www.jdrf.org
2
JDRF: Mission and General Strategy
To find a cure for diabetes and its complications
Proactively accelerate the discovery, development, and delivery of disease-modifying drugs and devices to
better treat and cure diabetes and its complications
3
Diabetes Market Landscape
• Cost of diabetes in US (2008) = $218 billon (direct and indirect costs: medical expenditures & lost productivity)• Diabetes Market (drugs & devices - worldwide sales, 2008):
– Insulin Products $9 billon– Drugs $8 billon– Blood Glucose Monitoring $7 billon– Insulin Pumps $1.5 billon
• Unmet medical need:– Help patients control glucose, stay healthy, and prevent complications – Develop new therapies and improve efficacy of existing therapies– Reduce overall cost of diabetes care and impact on the healthcare system
4
JDRF: Support
• Patient-centric organization: Cure, Treat, Prevent
• Over past 39 yrs, JDRF funded >$1B of research; FY10 research budget of $115M
• Funding potentially transformative early stage research, translational research, and clinical research in academia and industry worldwide
• Support also includes advocacy and addressing regulatory, reimbursement, adoption issues, etc.
• Partnering is critical for its success
5
JDRF: Partners
JDRF
VentureCapital
Industry
People with Type 1 Diabetes
Providers, Educators
Academia
Funders:NIH, Government, Foundations
FDA
Payers
JDRF
6
JDRF: Support
• Type 1 diabetes with type 2 diabetes impact
• All stages: At-risk, Recent onset, Established diabetes
7
JDRF: Diabetes Stage-Specific Focus
TreatPreventPrevent Treat
Cure
Established Diabetes
Recent Onset
DiabetesAt-Risk
8
JDRF: Support
• Type 1 diabetes with type 2 diabetes impact
• All stages: At-risk, Recent onset, Established diabetes
• Highest Funding Priorities
– Beta Cell Therapies: Beta Cell Regeneration and Reprogramming
– Immune Therapies: Antigen-Specific Immunotherapy and Vaccines
– Glucose Control: Closed Loop Artificial Pancreas Device, Glucose-responsive Insulin
– Complication Therapies: Complication protective therapies
• Proactively managed pipeline
9
JDRF: R&D Strategy
JDRF’s Role: To advance IP and product development by “de-risking”, increasing value, and filling gaps
Clinical Development
Translational Research
Basic Research
Patients
JDRF acts as a catalyst, driver, funder, advocate Partnering and handing off with “Line of Sight” to the Patient
JDRF: Industry Partners- 1Im
mun
e T
hera
pies
B
eta
Cel
lT
hera
pies
EU FP Funding (through Phase I )
JDRF: Industry Partners- 2G
luco
se C
ontr
ol
Com
plic
atio
nT
hera
pies
GNF-JDRF Partnership: Filling a Critical Gap
Deliver novel IND candidates for out-licensing or co-development with Novartis or other pharma
Deliver novel IND candidates for out-licensing or co-development with Novartis or other pharma
cell survival-Housey-GNF
.-GNF
cell survival-Kafman-Nadler-Others
-Stoffel- Kim- Newgard--Schreiber--Dor
Reprogram.-Hecksher-Sorensen-Schreiber
XOMA-052-Survival
Reprogram-Herrera-Ferber-Kay/Grompe-Bouwens-RFA pending
Progenitor cells-Sander/ Cirulli-Ferrer-Bonner-Weir- Bouwens
CellTarget
Path-way
TargetID
Lead IDLead
DevelopLead Optim
EIH Enable
Clinical Proof of concept
-Kim/Crabtree-Dor-Bhushan-Vale-Habener-Others
cell survival-Johnson-Zick\-Others
PPI/DPPIVi-Rabinovitch
Gastrin therapy-Transition
LeadingLeadingPharmaPharmaPartnersPartners
LeadingLeadingAcademicAcademicPartnersPartners
13
JDRF: Organizational Leadership
• Alan Lewis, PhD: President, CEO ([email protected])• Richard Insel, MD: EVP Research, CSO
([email protected])• Robert Goldstein, MD, PhD: SVP, Scientific Affairs
([email protected])• Karin Hehenberger, MD, PhD: SVP, Strategic
Alliances ([email protected])
14
JDRF: Summary/Key Points
• Focus on:– Patients: Cure, Treat, Prevent
– Science: Beta Cells, Immune Therapies, Glucose Control, Complications
– IP: Create IP and advance its development
• Execute through– Funding: Academia, Industry
– Outreach/Advocay: Patients, NIH, FDA, Insurance Industry, Providers
– Partnering: Industry, Foundations, VC
15
Q&A
